Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

FibroGen Inc (FGEN) Surges on Secondary Offering

Although most stocks generally decline on a secondary offering due to dilution, FibroGen Inc (NASDAQ:FGEN) is one of the exceptions today. Shares of the biotech have surged $3.50 per share, or 15%, on news that the company has priced an offering of 5.228 million shares at $22.95 a piece. Leerink Partners and Stifel are the joint book runners of the offering, which is expected to close on April 11, 2017. The secondary is expected to raise gross proceeds of $120 million, which presumably will help finance some R&D and potential commercialization down the road.

Although it has a lot of cash already, FibroGen Inc (NASDAQ:FGEN) management is playing it safe and adding more while its stock price is relatively high so that the company’s drug candidates such as pamrevlumab and roxadustat have all the support/resources it can get. If both drugs are approved and are commercial hits, FibroGen has substantial upside ahead.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

Smart money sentiment was relatively stable around FibroGen in the fourth quarter. Of the over 740 funds we track, 16 elite funds had a bullish position in FibroGen Inc (NASDAQ:FGEN) at the end of December, up one from the previous quarter. Lei Zhang‘s Hillhouse Capital Management was one of the bulls, almost doubling its stake to one million shares at the end of 2016.

The Bottom Line

FibroGen Inc (NASDAQ:FGEN) shares have surged higher due to a secondary offering. For more reading, check out ‘11 Most Sold Non Prescription Drugs‘.

Disclosure:None

Most Affordable Chemical Engineering Schools in The US

Loading...